John Hinton, MD
Neurology · Mobile, ALNPI 1982649182
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 71.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2021 at $8,371 and has fallen 92.8% since, to $607 in 2025.
Across 364 payments — averaging $61.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- UCB, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$708
- Novartis$523
- Biogen$191
- Pfizer$172
- plus $1K from 26 others
Across 18 payments — averaging $13,882 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$232K
- UCB Biosciences Inc.$16K
- UCB, Inc.$2K
What the payments were for
- Consulting fees$3,16314%
- Speaking & faculty fees$12,40056%
- Travel & lodging$8144%
- Food & beverage$5,83526%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 183 | $15,905 |
| UCB, Inc. | 12 | $3,563 |
| Teva Pharmaceuticals USA, Inc. | 43 | $708 |
| Novartis | 41 | $523 |
| Biogen | 11 | $191 |
| Pfizer | 10 | $172 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $142 |
| Acadia Pharmaceuticals Inc | 6 | $120 |
| Amgen(2 entities) | 6 | $107 |
| Bristol Myers Squibb | 8 | $100 |
| Johnson & Johnson | 5 | $73 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Lundbeck LLC | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| EMD Serono, Inc. | 4 | $52 |
| Upsher-smith Laboratories LLC | 3 | $39 |
| CSL Behring | 1 | $38 |
| Eisai Inc. | 2 | $38 |
| Argenx US, Inc. | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 3 | $34 |
| Tanabe Pharma America, Inc. | 2 | $31 |
| Catalyst Pharmaceuticals, Inc. | 2 | $29 |
| MDD US Operations, LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Abbott | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$13,251
- Zilbrysq$200
- Tecnis IOL$142
- AUSTEDO$116
How this compares
$22,254 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 17 | $201,192 |
| QuliptaAtogepant | 63 | $75,640 |
| NuplazidPimavanserin Tartrate | 13 | $63,636 |
| Nurtec OdtRimegepant Sulfate | 30 | $52,460 |
| UbrelvyUbrogepant | 42 | $47,634 |
| AptiomEslicarbazepine Acetate | 12 | $14,412 |
| ReyvowLasmiditan Succinate | 11 | $8,054 |
| Gabapentin | 224 | $3,674 |
| Pregabalin | 183 | $3,574 |
| Aripiprazole | 49 | $3,454 |
| Tizanidine Hcl | 125 | $2,985 |
| Oxcarbazepine | 16 | $2,522 |
| Levetiracetam | 88 | $1,992 |
| Piroxicam | 38 | $1,496 |
| Bupropion XlBupropion Hcl | 60 | $1,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $191 | $201,19217 claims |
| AbbVieQulipta, Ubrelvy | $15,905 | $123,274105 claims |
| Acadia Pharmaceuticals IncNuplazid | $120 | $63,63613 claims |
| PfizerNurtec Odt | $172 | $52,46030 claims |
| Upsher-smith Laboratories LLCTopiramate | $39 | $96984 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 neurology providers in Alabama.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Charles MarkleMobile$212K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Thomas FosterMobile$51K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.